Johnson & Johnson Total Cost of Revenue increased by 1.7% to $8.11B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.2%, from $7.36B to $8.11B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 6.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.59B | $7.25B | $1.50B | $7.60B | $7.92B | $6.17B | $6.08B | $6.69B | $6.46B | $6.61B | $6.80B | $6.51B | $6.87B | $6.96B | $7.13B | $7.36B | $7.63B | $7.30B | $7.97B | $8.11B |
| QoQ Change | — | -4.4% | -79.3% | +405.9% | +4.2% | -22.1% | -1.4% | +9.9% | -3.4% | +2.2% | +2.9% | -4.2% | +5.5% | +1.4% | +2.4% | +3.2% | +3.7% | -4.3% | +9.1% | +1.7% |
| YoY Change | — | — | — | — | +4.4% | -14.9% | +305.1% | -12.0% | -18.4% | +7.0% | +11.7% | -2.6% | +6.3% | +5.4% | +4.9% | +13.0% | +11.0% | +4.9% | +11.8% | +10.2% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Innovative Medicine | $4.02B | $3.98B | $3.67B | $3.98B | $4.39B |
| MEDTECH | $3.33B | $3.64B | $3.61B | $3.97B | $3.70B |
| Total | $7.36B | $7.63B | $7.30B | $7.97B | $8.11B |